Advertisement
Organisation › Details
Neuway Pharma GmbH
NEUWAY Pharma GmbH, Bonn, Germany, is focusing on the preclinical and clinical development of innovative therapeutics for treatment of orphan brain diseases based on its proprietary CNS drug delivery platform. The company also intends to partner its drug delivery technology for other CNS indications. NEUWAY had been founded in April 2014 as the first spin-off from Life Science Inkubator GmbH, Bonn, Germany, where it had been incubated for the last 4 years and supported with approx. € 2.3 million in research funding by the Federal Ministry of Education and Research. The company closed a series A financing round in May 2014 with a volume of € 2.7 million provided by a syndicate led by Wellington Partners. *
Start | 2014-04-09 splitoff | |
Predecessor | Life Science Inkubator GmbH (LSI) | |
Industry | CNS drug (neurological drug) | |
Industry 2 | drug delivery technology (drug formulation technology) | |
Person | Ernst, Oliver (Neuway Pharma 202210 CEO + Managing Director) | |
Person 2 | Scherhag, Rudi (Neuway Pharma 201508– Managing Director before ImClone Systems + Heidelberg Pharma + Roche Mannheim) | |
Region | Bonn | |
Country | Germany | |
Street | 2 Ludwig-Erhard-Allee c/o Life Science Inkubator GmbH | |
City | 53175 Bonn | |
Address record changed: 2022-09-18 | ||
Basic data | Employees | B: 11 to 50 (2018-02-01) |
* Document for »About Section«: | ||
Record changed: 2023-12-30 |
Advertisement
More documents for Neuway Pharma GmbH
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top